The drug label contains warnings with regard to increased risks of severe immune-mediated inflammation of the lungs, the colon, the liver, the kidneys (with accompanying kidney dysfunction), as well as immune-mediated hypothyroidism and hyperthyroidism. Hypothyroidism may affect 8.5% and hyperthyroidism 3.7%. Autoimmune diabetes similar to diabetes mellitus type 1 may occur in approximately 2% of people treated with<unk> . Colitis may occur due to nivolimumab. In trials for melanoma, the following side effects occurred in more than 10% of subjects and more frequently than with chemotherapy alone: rash and itchy skin, cough, upper respiratory tract infections, and peripheral edema. Other clinically important side effects with less than 10% frequency were ventricular arrhythmia, inflammation of parts of the eye (iridocyclitis), infusion-related reactions, dizziness, peripheral and sensory neuropathy, peeling skin, erythema multiforme, vitiligo, and psoriasis. In trials for lung cancer, the following side effects occurred in more than 10% of subjects and more frequently than with chemotherapy alone: fatigue, weakness, edema, fever, chest pain, generalized pain, shortness of breath, cough, muscle and joint pain, decreased appetite, abdominal pain, nausea and vomiting, constipation, weight loss, rash, and itchy skin. Levels of electrolytes and blood cells counts were also disrupted. Pregnancy and breastfeeding Use during pregnancy may harm the baby; it is not known if<unk>  is secreted in breast milk but use during breastfeeding is not recommended.
Nivolumab
Pembrolizumab
Risankizumab
Lirentelimab
Icotinib
Bamlanivimab/etesevimab
Obiltoxaximab
Daratumumab